Thumbs Up. Thumbs Down: On rook­ie mis­takes, a class ac­tion suit and get­ting past fail­ure

 
End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Por­to­la …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE